Clinical TrialAug 6, 2026, 08:04 AM
Ascendis Pharma Reports Strong TransCon CNP/hGH Combo Data; YUVIWEL Uptake
AI Summary
Ascendis Pharma provided positive updates on its achondroplasia programs, highlighting durable and unprecedented growth from its TransCon CNP and TransCon hGH combination therapy at Week 78. Monotherapy data for TransCon CNP also showed sustained improvements in height and body proportionality at Week 104. The company completed enrollment for its pivotal reACHin Trial and reported strong U.S. uptake for YUVIWEL, with over 170 patient enrollments and more than 65% approved for reimbursement.
Key Highlights
- TransCon CNP/hGH combination therapy showed mean AGV at or above 97th percentile at Week 78.
- TransCon CNP-naïve cohort achieved +1.29 ACH height Z-score increase over 78 weeks.
- TransCon CNP monotherapy demonstrated durable improvements in height and proportionality at Week 104.
- Completed target enrollment for pivotal reACHin Trial for infants 0 to <2 years with achondroplasia.
- Over 170 unique YUVIWEL patient enrollments in the U.S. through June 30, 2026.
- More than 65% of YUVIWEL enrollments approved for reimbursement.
- EU Marketing Authorisation decision for TransCon CNP monotherapy expected Q4 2026.
Price Impact
More from ASND